Art

J-GLOBAL ID：202002268095987901   Reference number：20A1854886

Treatment Result of Dulaglutide for Type-2 Diabetes in Shirakawa Kosei General Hospital

当科におけるデュラグルチド(トルリシティ)の使用経験

Author (2)： HIRAI HIROYUKI (白河厚生総合病院 第三内科) ,  KUSANO YOSHIRO (白河厚生総合病院 第三内科)
Material： 福島県農村医学会雑誌  (Fukushima Journal of Rural Medicine)
Volume： 60  Issue： 1  Page： 4-6  Publication year： Mar. 31, 2020 
JST Material Number： F0328C  ISSN： 0911-9426  Document type： Article
Article type： 短報  Country of issue： Japan (JPN)  Language： JAPANESE (JA)

Thesaurus term： human(primates) ,...
Semi thesaurus term： GLP-1 receptor agonist ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=20A1854886&from=J-GLOBAL&jstjournalNo=F0328C") }}

JST classification (1)： Treatment for metabolic diseases,nutritional diseases.  (GD05030F)

Substance index (1)： Metformin

Reference (11)：

• Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-Like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation 2017 ; 136 : 849-870.
• Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND) : a double-blind, randomised placebo-controlled trial. Lancet 2019 ; 394 : 121-130.
• Pharmacologic approaches to glycemic treatment : standards of medical care in diabetes-2019. Diabetes Care 2019 ; 42 : S 90- S 102.
• Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 ; 373 : 2117-2128.
• Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017 ; 377 : 644-657.

Terms in the title (3)： デュラグルチド ,  トルリシティ ,  経験